Gene Expression News and Research

RSS

Gene Expression is the process by which a gene gets turned on in a cell to make RNA and proteins. Gene expression may be measured by looking at the RNA, or the protein made from the RNA, or what the protein does in a cell.

Researchers reprogram human embryonic stem cells to iPS cells for use in regenerative medicine

Human embryonic stem (ES) cells and adult cells reprogrammed to an embryonic stem cell-like state-so-called induced pluripotent stem or iPS cells-exhibit very few differences in their gene expression signatures and are nearly indistinguishable in their chromatin state, according to Whitehead Institute researchers.The pluripotency of ES cells fueled excitement over their use in regenerative medicine. While ethical hurdles associated with the clinical application of human ES cells appeared to have been overcome with the development of methods to create iPS cells, some recent research has suggested that ES and iPS cells have substantial differences in which sets of genes they express.

6 Aug 2010

WaferGen launches SmartChip System for discovery, validation of biomarkers

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced it has launched the breakthrough WaferGen SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

6 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Ferroportin levels are strong predictors of propensity for breast cancer recurrence: Study

A new study by researchers at Wake Forest University Baptist Medical Center (WFUBMC) may soon help to spare some women with breast cancer from having to undergo invasive and toxic treatments for their disease.

5 Aug 2010

Rush University Medical Center first to receive Octapharma grant under anniversary program

Octapharma USA today announced the first grant recipient of the Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center. The Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

3 Aug 2010

miRagen Therapeutics develop MicroRNA based therapeutics for cardiovascular and muscle disease

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.

3 Aug 2010

Scientists discover technique for more controlled lab experiments on cellular mechanobiology

Bioengineers at the University of Pennsylvania have created a system to control the flexibility of the substrate surfaces on which cells are grown without changing the surface properties, providing a technique for more controlled lab experiments on cellular mechanobiology, an important step in the scientific effort to understand how cells sense and respond to mechanical forces in their environment.

2 Aug 2010

Epigenetic changes to DNA in breast cancers linked with environmental risk factors, tumor size: Study

Researchers from Brown University and the University of California San Francisco have found that epigenetic changes to DNA in breast cancers are related to environmental risk factors and tumor size, providing a window into the severity of the disease. The study is published in today's edition of PLoS Genetics. The researchers found that epigenetic profiles of tumors had a direct association with diet, alcohol, and tumor size.

31 Jul 2010

Exact Sciences to demonstrate methylation specific technology at AACC annual meeting

Exact Sciences Corp. today announced that data being presented this afternoon at the annual meeting of the American Association of Clinical Chemistry demonstrates that its methylation specific technology, using a combination of DNA methylation markers, detected 100 percent of colorectal cancers and precancers at a specificity cutoff of 100 percent in a preliminary study with colorectal tissue.

29 Jul 2010

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.

29 Jul 2010

Genetic interaction with diet causes variations in metabolic traits

Ever notice some people seem to eat anything they want and never gain a pound, while others seem to gain weight just by looking at fattening foods. You may be seeing things correctly after all. According to research published in the July 2010 issue of Genetics, this may have a biological cause. Using fruit flies, researchers have found that genes interacting with diet, rather than diet alone, are the main cause of variation in metabolic traits, such as body weight. This helps explain why some diets work better for some people than others, and suggests that future diets should be tailored to an individual's genes rather than to physical appearance.

29 Jul 2010

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

29 Jul 2010

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.

28 Jul 2010

Clontech Laboratories, TET Systems expand license agreement

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems (TET), a privately-held German biotech company based in Heidelberg, today announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains rights to develop, manufacture and commercialize novel Tet Systems products as the Tet-On® 3G™ Inducible Expression System.

26 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

Maven Semantic announces updates to Bioinformatics medical professionals database

Maven Semantic announces updates to their Bioinformatics database.

23 Jul 2010

Gene expression profiling may provide molecular diagnostic tool to diagnose depression

Blood tests have been extremely important tools aiding doctors in making medical diagnoses and in guiding the treatment of many diseases. However, psychiatry is one area of medicine where there are few diagnostic blood tests.New scientific fields may someday generate blood tests that can be used for these purposes. Some of the areas under increasingly intensive study are genetics, the study of variations in the genes that can be extracted from blood cells, and genomics like proteomics, the measurement of the levels of specific proteins in the blood, and gene expression profiling, which measures the levels of RNA produced from DNA as an indication of the level of the "activity" of particular genes.

23 Jul 2010

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute.Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism, said Bruce Spiegelman, PhD, of Dana-Farber, senior author on a report appearing in the July 22 issue of Nature.

22 Jul 2010

Affymetrix launches QuantiGene ViewRNA Assay formats

Affymetrix, Inc. today announced the launch of QuantiGene® ViewRNA Assay formats, which enable a new era of "in situ multiplex gene expression analysis" by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies. These in situ assays enable researchers to visualize gene expression in individual cells at an unprecedented level of sensitivity and speed.

22 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

Gene Expression News and Research

Further Reading

Researchers reprogram human embryonic stem cells to iPS cells for use in regenerative medicine

WaferGen launches SmartChip System for discovery, validation of biomarkers

Alnylam second-quarter revenues increase to $26.6 million

Ferroportin levels are strong predictors of propensity for breast cancer recurrence: Study

Rush University Medical Center first to receive Octapharma grant under anniversary program

miRagen Therapeutics develop MicroRNA based therapeutics for cardiovascular and muscle disease

Scientists discover technique for more controlled lab experiments on cellular mechanobiology

Epigenetic changes to DNA in breast cancers linked with environmental risk factors, tumor size: Study

Exact Sciences to demonstrate methylation specific technology at AACC annual meeting

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Genetic interaction with diet causes variations in metabolic traits

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Clontech Laboratories, TET Systems expand license agreement

Axela acquires Xceed Molecular

Maven Semantic announces updates to Bioinformatics medical professionals database

Gene expression profiling may provide molecular diagnostic tool to diagnose depression

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

Affymetrix launches QuantiGene ViewRNA Assay formats

Affymetrix second-quarter total revenue decreases to $71.7 million

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News